P-selectin antagonism in inflammatory disease

Current Pharmaceutical Design

Volumn 16, Issue 37, 2010, Pages 4113-4118

  Woollard, Kevin J ^a   Chin Dusting, Jaye ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Atherosclerosis; Cellular adhesion; Endothelium; Inflammation; Leukocyte; P selectin

Indexed keywords

4 RA10; ABC 48; BIMOSIAMOSE; CARDIOVASCULAR AGENT; CDP 850; CONTRAST MEDIUM; CY 1503; GLYSOPEP; HUEPSC7 G2; KF 38789; MAGNETIC NANOPARTICLE P SELECTIN BINDING PEPTIDE; P SELECTIN BINDING PEPTIDE; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PS 1697; PSELMABG1; RB40 34; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; ATHEROSCLEROSIS; CELL ADHESION; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM; HUMAN; INFLAMMATION; LEUKOCYTE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS;

ANIMALS; ATHEROSCLEROSIS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; LEUKOCYTES; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; P-SELECTIN; PLATELET ACTIVATION; THROMBOSIS;

EID: 79952729166     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210794519192     Document Type: Article

References (92)

1. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
2. Woollard KJ, Chin-Dusting J. Therapeutic targeting of p-selectin in atherosclerosis. Inflamm Allergy Drug Targets 2007; 6: 69-74.
3. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272: 60-66.
4. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 1996; 88: 3259-3287.
5. Woollard KJ. Soluble bio-markers in vascular disease: much more than gauges of disease? Clin Exp Pharmacol Physiol 2005; 32: 233-240.
6. Kelly M, Hwang JM, Kubes P. Modulating leukocyte recruitment in inflammation. J Allergy Clin Immunol 2007; 120: 3-10.
7. Patel KD, Nollert MU, McEver RP. P-selectin must extend a sufficient length from the plasma membrane to mediate rolling of neutrophils. J Cell Biol 1995; 131: 1893-1902.
8. Wenzel K, Felix S, Kleber FX, et al. E-selectin polymorphism and atherosclerosis: an association study. Hum Mol Genet 1994; 3: 1935-1937.
9. Wenzel K, Hanke R, Speer A. Polymorphism in the human Eselectin gene detected by PCR-SSCP. Hum Genet 1994; 94: 452-453.
10. Kansas GS, Saunders KB, Ley K, et al. A role for the epidermal growth factor-like domain of P-selectin in ligand recognition and cell adhesion. J Cell Biol 1994; 124: 609-618.
11. Gibson RM, Kansas GS, Tedder TF, Furie B, Furie BC. Lectin and epidermal growth factor domains of P-selectin at physiologic density are the recognition unit for leukocyte binding. Blood 1995; 85: 151-158.
12. Li SH, Burns DK, Rumberger JM, et al. Consensus repeat domains of E-selectin enhance ligand binding. J Biol Chem 1994; 269: 4431-4437.
13. Barthel SR, Gavino JD, Descheny L, Dimitroff CJ. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets 2007; 11: 1473-1491.
14. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068-2101.
15. Frenette PS, Denis CV, Weiss L, et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000; 191: 1413-1422.
16. Ramachandran V, Yago T, Epperson TK, et al. Dimerization of a selectin and its ligand stabilizes cell rolling and enhances tether strength in shear flow. Proc Natl Acad Sci USA 2001; 98: 10166-10171.
17. Epperson TK, Patel KD, McEver RP, Cummings RD. Noncovalent association of P-selectin glycoprotein ligand-1 and minimal determinants for binding to P-selectin. J Biol Chem 2000; 275: 7839-7853.
18. Yang J, Hirata T, Croce K, et al. Targeted gene disruption demonstrates that P-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration. J Exp Med 1999; 190: 1769-1782.
19. Evangelista V, Manarini S, Coller BS, Smyth SS. Role of Pselectin, beta2-integrins, and Src tyrosine kinases in mouse neutrophil-platelet adhesion. J Thromb Haemost 2003; 1: 1048-1054.
20. Urzainqui A, Serrador JM, Viedma F, et al. ITAM-based interaction of ERM proteins with Syk mediates signaling by the leukocyte adhesion receptor PSGL-1. Immunity 2002; 17: 401-412.
21. Simon SI, Goldsmith HL. Leukocyte adhesion dynamics in shear flow. Ann Biomed Eng 2002; 30: 315-332.
22. Takagi J, Springer TA. Integrin activation and structural rearrangement. Immunol Rev 2002; 186: 141-163.
23. Johnston GI, Cook RG, McEver RP. Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. Cell 1989; 56: 1033-1044.
24. Kameda H, Morita I, Handa M, et al. Re-expression of functional P-selectin molecules on the endothelial cell surface by repeated stimulation with thrombin. Br J Haematol 1997; 97: 348-355.
25. Khew-Goodall Y, Butcher CM, Litwin MS, et al. Chronic expression of P-selectin on endothelial cells stimulated by the T-cell cytokine, interleukin-3. Blood 1996; 87: 1432-1438.
26. Gotsch U, Jager U, Dominis M, Vestweber D. Expression of Pselectin on endothelial cells is upregulated by LPS and TNF-alpha in vivo. Cell Adhes Commun 1994; 2: 7-14.
27. Semenov AV, Romanov YA, Loktionova SA, et al. Production of soluble P-selectin by platelets and endothelial cells. Biochemistry (Mosc) 1999; 64: 1326-1335.
28. Matzdorff AC, Kemkes-Matthes B, Voss R, Pralle H. Comparison of beta-thromboglobulin, flow cytometry, and platelet aggregometry to study platelet activation. Haemostasis 1996; 26: 98-106.
29. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001; 86: 746-756.
30. Elstad MR, La Pine TR, Cowley FS, et al. P-selectin regulates platelet-activating factor synthesis and phagocytosis by monocytes. J Immunol 1995; 155: 2109-2122.
31. Furie B, Furie BC. P-selectin induction of tissue factor biosynthesis and expression. Haemostasis 1996; 26 (Suppl 1): 60-65.
32. Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA 1994; 91: 8767-8771.
33. Kisucka J, Chauhan AK, Zhao BQ, et al. Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis. Blood 2009; 113: 6015-6022.
34. Woollard KJ, Kling D, Kulkarni S, Dart AM, Jackson S, Chin-Dusting J. Raised plasma soluble P-selectin in peripheral arterial occlusive disease enhances leukocyte adhesion. Circ Res 2006; 98: 149-156.
35. Galkina E, Ley K. Double jeopardy: how soluble P-selectin activates leukocytes in peripheral arterial occlusive disease. Circ Res 2006; 98: 12-14.
36. Woollard KJ, Suhartoyo A, Harris EE, et al. Pathophysiological levels of soluble P-selectin mediate adhesion of leukocytes to the endothelium through Mac-1 activation. Circ Res 2008; 103: 1128-1138.
37. Wagner DD. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2005; 25: 1321-1324.
38. Dong ZM, Brown AA, Wagner DD. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation 2000; 101: 2290-2295.
39. Nageh MF, Sandberg ET, Marotti KR, et al. Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1997; 17: 1517-1520.
40. Kumar A, Hoover JL, Simmons CA, Lindner V, Shebuski RJ. Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. Circulation 1997; 96: 4333-4342.
41. Manka D, Collins RG, Ley K, Beaudet AL, Sarembock IJ. Absence of p-selectin, but not intercellular adhesion molecule-1, attenuates neointimal growth after arterial injury in apolipoprotein e-deficient mice. Circulation 2001; 103: 1000-1005.
42. Dore M, Korthuis RJ, Granger DN, Entman ML, Smith CW. Pselectin mediates spontaneous leukocyte rolling in vivo. Blood 1993; 82: 1308-1316.
43. Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 1990; 75: 550-554.
44. Palabrica T, Lobb R, Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-851.
45. Buttrum SM, Hatton R, Nash GB. Selectin-mediated rolling of neutrophils on immobilized platelets. Blood 1993; 82: 1165-1174.
46. Yeo EL, Sheppard JA, Feuerstein IA. Role of P-selectin and leukocyte activation in polymorphonuclear cell adhesion to surface adherent activated platelets under physiologic shear conditions (an injury vessel wall model). Blood 1994; 83: 2498-2507.
47. Norman KE, Katopodis AG, Thoma G, et al. P-selectin glycoprotein ligand-1 supports rolling on E- and P-selectin in vivo. Blood 2000; 96: 3585-3591.
48. Johnson-Tidey RR, McGregor JL, Taylor PR, Poston RN. Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques. Coexpression with intercellular adhesion molecule- 1. Am J Pathol 1994; 144: 952-961.
49. Poston RN, Johnson-Tidey RR. Localized adhesion of monocytes to human atherosclerotic plaques demonstrated in vitro: implications for atherogenesis. Am J Pathol 1996; 149: 73-80.
50. Okada Y, Copeland BR, Mori E, Tung MM, Thomas WS, del Zoppo GJ. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke 1994; 25: 202-211.
51. Tenaglia AN, Buda AJ, Wilkins RG, et al. Levels of expression of P-selectin, E-selectin, and intercellular adhesion molecule-1 in coronary atherectomy specimens from patients with stable and unstable angina pectoris. Am J Cardiol 1997; 79: 742-747.
52. Wang K, Zhou Z, Zhou X, Tarakji K, Topol EJ, Lincoff AM. Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model. J Am Coll Cardiol 2001; 38: 577-582.
53. Wang K, Zhou X, Zhou Z, et al. Platelet, not endothelial, P-selectin is required for neointimal formation after vascular injury. Arterioscler Thromb Vasc Biol 2005; 25: 1584-1589.
54. Zhou Z, Penn MS, Forudi F, et al. Administration of recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model. Arterioscler Thromb Vasc Biol 2002; 22: 1598-1603.
55. Owens R, Ball E, Ganesh R, et al. The in vivo and in vitro characterization of an engineered human antibody to E-selectin. Immunotechnology 1997; 3: 107-116.
56. Bhushan M, Bleiker TO, Ballsdon AE, et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br J Dermatol 2002; 146: 824-831.
57. Lin CL, Dumont AS, Calisaneller T, Kwan AL, Hwong SL, Lee KS. Monoclonal antibody against E selectin attenuates subarachnoid hemorrhage-induced cerebral vasospasm. Surg Neurol 2005; 64: 201-205; discussion 5-6.
58. He XY, Xu Z, Melrose J, et al. Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and Pselectin. J Immunol 1998; 160: 1029-1035.
59. Li B, New JY, Tay YK, et al. Delaying acute graft-versus-host disease in mouse bone marrow transplantation by treating donor cells with antibodies directed at l-selectin and alpha4-integrin prior to infusion. Scand J Immunol 2004; 59: 464-468.
60. Opal SM, Sypek JP, Keith JC, Jr., Schaub RG, Palardy JE, Parejo NA. Evaluation of the safety of recombinant P-selectin glycoprotein ligand-immunoglobulin G fusion protein in experimental models of localized and systemic infection. Shock 2001; 15: 285-290.
61. Kumar A, Villani MP, Patel UK, Keith JC, Jr., Schaub RG. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation 1999; 99: 1363-1339.
62. Farmer DG, Anselmo D, Da Shen X, et al. Disruption of P-selectin signaling modulates cell trafficking and results in improved outcomes after mouse warm intestinal ischemia and reperfusion injury. Transplantation 2005; 80: 828-835.
63. Hansen A, Kumar A, Wolf D, et al. Evaluation of cardioprotective effects of recombinant soluble P-selectin glycoprotein ligandimmunoglobulin in myocardial ischemia-reperfusion injury by realtime myocardial contrast echocardiography. J Am Coll Cardiol 2004; 44: 887-891.
64. Bienvenu JG, Tanguay JF, Theoret JF, Kumar A, Schaub RG, Merhi Y. Recombinant soluble p-selectin glycoprotein ligand-1-Ig reduces restenosis through inhibition of platelet-neutrophil adhesion after double angioplasty in swine. Circulation 2001; 103: 1128-1134.
65. Romano SJ. Selectin antagonists: therapeutic potential in asthma and COPD. Treat Respir Med 2005; 4: 85-94.
66. Tsuchihashi S, Fondevila C, Shaw GD, et al. Molecular characterization of rat leukocyte P-selectin glycoprotein ligand-1 and effect of its blockade: protection from ischemia-reperfusion injury in liver transplantation. J Immunol 2006; 176: 616-624.
67. Phillips JW, Barringhaus KG, Sanders JM, et al. Single injection of P-selectin or P-selectin glycoprotein ligand-1 monoclonal antibody blocks neointima formation after arterial injury in apolipoprotein Edeficient mice. Circulation 2003; 107: 2244-2249.
68. Alon R, Feizi T, Yuen CT, Fuhlbrigge RC, Springer TA. Glycolipid ligands for selectins support leukocyte tethering and rolling under physiologic flow conditions. J Immunol 1995; 154: 5356-5366.
69. Nelson RM, Dolich S, Aruffo A, Cecconi O, Bevilacqua MP. Higher-affinity oligosaccharide ligands for E-selectin. J Clin Invest 1993; 91: 1157-1166.
70. Koenig A, Jain R, Vig R, Norgard-Sumnicht KE, Matta KL, Varki A. Selectin inhibition: synthesis and evaluation of novel sialylated, sulfated and fucosylated oligosaccharides, including the major capping group of GlyCAM-1. Glycobiology 1997; 7: 79-93.
71. Dube DH, Bertozzi CR. Glycans in cancer and inflammation-- potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005; 4: 477-488.
72. Compain P, Martin OR. Carbohydrate mimetics-based glycosyltransferase inhibitors. Bioorg Med Chem 2001; 9: 3077-3092.
73. Mitchell ML, Tian F, Lee LV, Wong CH. Synthesis and evaluation of transition-state analogue inhibitors of alpha-1,3-fucosyltransferase. Angew Chem Int Ed Engl 2002; 41: 3041-3014.
74. Cappi MW, Moree WJ, Qiao L, Marron TG, Weitz-Schmidt G, Wong CH. Synthesis of novel 6-amido-6-deoxy-l-galactose derivatives as sialyl Lewis X mimetics. Bioorg Med Chem 1997; 5: 283-296.
75. Murohara T, Margiotta J, Phillips LM, et al. Cardioprotection by liposome-conjugated sialyl Lewisx-oligosaccharide in myocardial ischaemia and reperfusion injury. Cardiovasc Res 1995; 30: 965-974.
76. Oostingh GJ, Ludwig RJ, Enders S, et al. Diminished lymphocyte adhesion and alleviation of allergic responses by small-moleculeor antibody-mediated inhibition of L-selectin functions. J Invest Dermatol 2007; 127: 90-97.
77. Schon MP, Krahn T, Schon M, et al. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med 2002; 8: 366-372.
78. Kaila N, Thomas BEt. Design and synthesis of sialyl Lewis(x) mimics as E- and P-selectin inhibitors. Med Res Rev 2002; 22: 566-601.
79. Onai Y, Suzuki J, Nishiwaki Y, et al. Blockade of cell adhesion by a small molecule selectin antagonist attenuates myocardial ischemia/ reperfusion injury. Eur J Pharmacol 2003; 481: 217-225.
80. Meyer M, Jilma B, Zahlten R, Wolff G. Physiochemical properties, safety and pharmacokinetics of bimosiamose disodium after intravenous administration. Int J Clin Pharmacol Ther 2005; 43: 463-471.
81. Beeh KM, Beier J, Meyer M, Buhl R, Zahlten R, Wolff G. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm Pharmacol Ther 2006; 19: 233-241.
82. Santos RD, Nasir K. Insights into atherosclerosis from invasive and non-invasive imaging studies: Should we treat subclinical atherosclerosis? Atherosclerosis 2009; 205: 349-356.
83. Keelan ET, Harrison AA, Chapman PT, Binns RM, Peters AM, Haskard DO. Imaging vascular endothelial activation: an approach using radiolabeled monoclonal antibodies against the endothelial cell adhesion molecule E-selectin. J Nucl Med 1994; 35: 276-281.
84. Jamar F, Houssiau FA, Devogelaer JP, et al. Scintigraphy using a technetium 99m-labelled anti-E-selectin Fab fragment in rheumatoid arthritis. Rheumatology (Oxford) 2002; 41: 53-61.
85. Bhatti M, Chapman P, Peters M, Haskard D, Hodgson HJ. Visualising E-selectin in the detection and evaluation of inflammatory bowel disease. Gut 1998; 43: 40-47.
86. Barber PA, Foniok T, Kirk D, et al. MR molecular imaging of early endothelial activation in focal ischemia. Ann Neurol 2004; 56: 116-120.
87. Boutry S, Burtea C, Laurent S, Toubeau G, Vander Elst L, Muller RN. Magnetic resonance imaging of inflammation with a specific selectin-targeted contrast agent. Magn Reson Med 2005; 53: 800-807.
88. Licha K, Debus N, Emig-Vollmer S, et al. Optical molecular imaging of lymph nodes using a targeted vascular contrast agent. J Biomed Opt 2005; 10: 41205.
89. Funovics M, Montet X, Reynolds F, Weissleder R, Josephson L. Nanoparticles for the optical imaging of tumor E-selectin. Neoplasia 2005; 7: 904-911.
90. Jin AY, Tuor UI, Rushforth D, et al. Magnetic resonance molecular imaging of post-stroke neuroinflammation with a P-selectin targeted iron oxide nanoparticle. Contrast Media Mol Imaging 2009; 4: 305-311.
91. Weller GE, Villanueva FS, Tom EM, Wagner WR. Targeted ultrasound contrast agents: in vitro assessment of endothelial dysfunction and multi-targeting to ICAM-1 and sialyl Lewisx. Biotechnol Bioeng 2005; 92: 780-788.
92. Lehmberg J, Beck J, Baethmann A, Uhl E. Effect of P-selectin inhibition on leukocyte-endothelium interaction and survival after global cerebral ischemia. J Neurol 2006; 253: 357-363.